Physician profile
Christopher D Moore
NPI 1669552030
$2,895.68
in general payments reported to CMS, 2019-2025
25 companies · $621 in 2025
The $621 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $92.43 · 2021: $245 · 2022: $320 · 2023: $697 · 2024: $515 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,832.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $366.94 | 2019-2024 | Cook |
| Astellas Pharma US INC | $318.47 | 2019-2025 | Xtandi |
| Ambu INC. | $310.19 | 2023-2025 | |
| Teleflex LLC | $204.87 | 2022-2025 | Barrigel |
| Abbvie INC. | $200.46 | 2022-2025 | |
| Boston Scientific Corporation | $187.94 | 2022-2025 | Lithovue, Bulkamid |
| Pfizer INC. | $161.25 | 2019-2023 | |
| Calyxo, INC. | $159.11 | 2024-2025 | Cvac Aspiration System |
| Endo Pharmaceuticals INC. | $140.59 | 2019-2023 | Xiaflex |
| Karl Storz Endoscopy-America | $137.47 | 2023 | Flex-X |
| Axonics, INC. | $114.75 | 2023 | Axonics |
| Ferring Pharmaceuticals INC. | $109.64 | 2025 | Adstiladrin |
| Sumitomo Pharma America, INC. | $83.88 | 2023-2025 | Gemtesa |
| 180 Medical, INC. | $56.62 | 2020-2025 | Gentlecath |
| Novartis Pharmaceuticals Corporation | $48.46 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rochester Medical Corporation | $44.04 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $43.49 | 2021-2024 | Bard Urinary Drainage Bag |
| Olympus America INC. | $41.94 | 2022-2025 | Itind System |
| Coloplast Corp | $39.81 | 2023-2025 | Titan |
| Janssen Biotech, INC. | $33.27 | 2021 | |
| Tolmar, INC. | $22.24 | 2023 | |
| Mission Pharmacal Company | $21.00 | 2021 | |
| Neotract INC. | $20.85 | 2019 | |
| Allergan, INC. | $14.49 | 2019 | |
| Convatec INC. | $13.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.